BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38769568)

  • 1. Activated phosphoinositde 3-kinase (PI3Kδ) syndrome: an Italian point of view on diagnosis and new advances in treatment.
    Lougaris V; Piane FL; Cancrini C; Conti F; Tommasini A; Badolato R; Trizzino A; Zecca M; De Rosa A; Barzaghi F; Pignata C
    Ital J Pediatr; 2024 May; 50(1):103. PubMed ID: 38769568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective "activated PI3Kδ syndrome"-targeted therapy with the PI3Kδ inhibitor leniolisib.
    Rao VK; Webster S; Dalm VASH; Šedivá A; van Hagen PM; Holland S; Rosenzweig SD; Christ AD; Sloth B; Cabanski M; Joshi AD; de Buck S; Doucet J; Guerini D; Kalis C; Pylvaenaeinen I; Soldermann N; Kashyap A; Uzel G; Lenardo MJ; Patel DD; Lucas CL; Burkhart C
    Blood; 2017 Nov; 130(21):2307-2316. PubMed ID: 28972011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical, Immunological, and Genetic Features in Patients with Activated PI3Kδ Syndrome (APDS): a Systematic Review.
    Jamee M; Moniri S; Zaki-Dizaji M; Olbrich P; Yazdani R; Jadidi-Niaragh F; Aghamahdi F; Abolhassani H; Condliffe AM; Aghamohammadi A; Azizi G
    Clin Rev Allergy Immunol; 2020 Dec; 59(3):323-333. PubMed ID: 31111319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Treatment of Activated PI3Kδ Syndrome.
    Coulter TI; Cant AJ
    Front Immunol; 2018; 9():2043. PubMed ID: 30245694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PI3Kδ Pathway Dysregulation and Unique Features of Its Inhibition by Leniolisib in Activated PI3Kδ Syndrome and Beyond.
    Cant AJ; Chandra A; Munro E; Rao VK; Lucas CL
    J Allergy Clin Immunol Pract; 2024 Jan; 12(1):69-78. PubMed ID: 37777067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interim analysis: Open-label extension study of leniolisib for patients with APDS.
    Rao VK; Kulm E; Šedivá A; Plebani A; Schuetz C; Shcherbina A; Dalm VA; Trizzino A; Zharankova Y; Webster S; Orpia A; Körholz J; Lougaris V; Rodina Y; Radford K; Bradt J; Relan A; Holland SM; Lenardo MJ; Uzel G
    J Allergy Clin Immunol; 2024 Jan; 153(1):265-274.e9. PubMed ID: 37797893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulating the PI3K Signalling Pathway in Activated PI3K Delta Syndrome: a Clinical Perspective.
    Berglund LJ
    J Clin Immunol; 2023 Dec; 44(1):34. PubMed ID: 38148368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study.
    Coulter TI; Chandra A; Bacon CM; Babar J; Curtis J; Screaton N; Goodlad JR; Farmer G; Steele CL; Leahy TR; Doffinger R; Baxendale H; Bernatoniene J; Edgar JD; Longhurst HJ; Ehl S; Speckmann C; Grimbacher B; Sediva A; Milota T; Faust SN; Williams AP; Hayman G; Kucuk ZY; Hague R; French P; Brooker R; Forsyth P; Herriot R; Cancrini C; Palma P; Ariganello P; Conlon N; Feighery C; Gavin PJ; Jones A; Imai K; Ibrahim MA; Markelj G; Abinun M; Rieux-Laucat F; Latour S; Pellier I; Fischer A; Touzot F; Casanova JL; Durandy A; Burns SO; Savic S; Kumararatne DS; Moshous D; Kracker S; Vanhaesebroeck B; Okkenhaug K; Picard C; Nejentsev S; Condliffe AM; Cant AJ
    J Allergy Clin Immunol; 2017 Feb; 139(2):597-606.e4. PubMed ID: 27555459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful haploidentical hematopoietic stem cell transplantation for activated phosphoinositide 3-kinase δ syndrome: Case report and literature review.
    Yang X; Xi R; Bai J; Pan Y
    Medicine (Baltimore); 2023 Feb; 102(5):e32816. PubMed ID: 36749229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activated phosphoinositide 3-dinase delta syndrome (APDS): An update.
    Lougaris V; Cancrini C; Rivalta B; Castagnoli R; Giardino G; Volpi S; Leonardi L; La Torre F; Federici S; Corrente S; Cinicola BL; Soresina A; Marseglia GL; Cardinale F
    Pediatr Allergy Immunol; 2022 Jan; 33 Suppl 27(Suppl 27):69-72. PubMed ID: 35080319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activated PI3 Kinase Delta Syndrome: From Genetics to Therapy.
    Michalovich D; Nejentsev S
    Front Immunol; 2018; 9():369. PubMed ID: 29535736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term treatment with selective PI3Kδ inhibitor leniolisib in adults with activated PI3Kδ syndrome.
    Rao VK; Kulm E; Grossman J; Buchbinder D; Chong H; Bradt J; Webster S; Šedivá A; Dalm VA; Uzel G
    Blood Adv; 2024 Jun; 8(12):3092-3108. PubMed ID: 38593221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activated phosphoinositide 3-kinase δ syndrome: Update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity.
    Maccari ME; Wolkewitz M; Schwab C; Lorenzini T; Leiding JW; Aladjdi N; Abolhassani H; Abou-Chahla W; Aiuti A; Azarnoush S; Baris S; Barlogis V; Barzaghi F; Baumann U; Bloomfield M; Bohynikova N; Bodet D; Boutboul D; Bucciol G; Buckland MS; Burns SO; Cancrini C; Cathébras P; Cavazzana M; Cheminant M; Chinello M; Ciznar P; Coulter TI; D'Aveni M; Ekwall O; Eric Z; Eren E; Fasth A; Frange P; Fournier B; Garcia-Prat M; Gardembas M; Geier C; Ghosh S; Goda V; Hammarström L; Hauck F; Heeg M; Heropolitanska-Pliszka E; Hilfanova A; Jolles S; Karakoc-Aydiner E; Kindle GR; Kiykim A; Klemann C; Koletsi P; Koltan S; Kondratenko I; Körholz J; Krüger R; Jeziorski E; Levy R; Le Guenno G; Lefevre G; Lougaris V; Marzollo A; Mahlaoui N; Malphettes M; Meinhardt A; Merlin E; Meyts I; Milota T; Moreira F; Moshous D; Mukhina A; Neth O; Neubert J; Neven B; Nieters A; Nove-Josserand R; Oksenhendler E; Ozen A; Olbrich P; Perlat A; Pac M; Schmid JP; Pacillo L; Parra-Martinez A; Paschenko O; Pellier I; Sefer AP; Plebani A; Plantaz D; Prader S; Raffray L; Ritterbusch H; Riviere JG; Rivalta B; Rusch S; Sakovich I; Savic S; Scheible R; Schleinitz N; Schuetz C; Schulz A; Sediva A; Semeraro M; Sharapova SO; Shcherbina A; Slatter MA; Sogkas G; Soler-Palacin P; Speckmann C; Stephan JL; Suarez F; Tommasini A; Trück J; Uhlmann A; van Aerde KJ; van Montfrans J; von Bernuth H; Warnatz K; Williams T; Worth AJJ; Ip W; Picard C; Catherinot E; Nademi Z; Grimbacher B; Forbes Satter LR; Kracker S; Chandra A; Condliffe AM; Ehl S;
    J Allergy Clin Immunol; 2023 Oct; 152(4):984-996.e10. PubMed ID: 37390899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Future Directions in the Diagnosis and Treatment of APDS and IEI: a Survey of German IEI Centers.
    Vanselow S; Hanitsch L; Hauck F; Körholz J; Maccari ME; Meinhardt A; Sogkas G; Schuetz C; Grimbacher B
    Front Immunol; 2023; 14():1279652. PubMed ID: 37868971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Respiratory Manifestations of the Activated Phosphoinositide 3-Kinase Delta Syndrome.
    Condliffe AM; Chandra A
    Front Immunol; 2018; 9():338. PubMed ID: 29556229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome.
    Rao VK; Webster S; Šedivá A; Plebani A; Schuetz C; Shcherbina A; Conlon N; Coulter T; Dalm VA; Trizzino A; Zharankova Y; Kulm E; Körholz J; Lougaris V; Rodina Y; Radford K; Bradt J; Kucher K; Relan A; Holland SM; Lenardo MJ; Uzel G
    Blood; 2023 Mar; 141(9):971-983. PubMed ID: 36399712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoimmune Cytopenias and Dysregulated Immunophenotype Act as Warning Signs of Inborn Errors of Immunity: Results From a Prospective Study.
    Schiavo E; Martini B; Attardi E; Consonni F; Ciullini Mannurita S; Coniglio ML; Tellini M; Chiocca E; Fotzi I; Luti L; D'Alba I; Veltroni M; Favre C; Gambineri E
    Front Immunol; 2021; 12():790455. PubMed ID: 35058929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activated PI3Kδ syndrome type 2: Two patients, a novel mutation, and review of the literature.
    Olbrich P; Lorenz M; Cura Daball P; Lucena JM; Rensing-Ehl A; Sanchez B; Führer M; Camacho-Lovillo M; Melon M; Schwarz K; Neth O; Speckmann C
    Pediatr Allergy Immunol; 2016 Sep; 27(6):640-4. PubMed ID: 27116393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activated PI3Kδ syndrome - reviewing challenges in diagnosis and treatment.
    Vanselow S; Wahn V; Schuetz C
    Front Immunol; 2023; 14():1208567. PubMed ID: 37600808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activated Phosphoinositide 3-Kinase δ Syndrome: a Large Pediatric Cohort from a Single Center in China.
    Qiu L; Wang Y; Tang W; Yang Q; Zeng T; Chen J; Chen X; Zhang L; Zhou L; Zhang Z; An Y; Tang X; Zhao X
    J Clin Immunol; 2022 May; 42(4):837-850. PubMed ID: 35296988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.